If so that may result in a 2 to 3 point increase in of itself.
First Data’s Big Role in New Apple Payment Plan
By ROBIN SIDEL, CONNECT
Apple demonstrates paying using Apple Pay with the new Apple Watch. Wilson Rothman for The Wall Street Journal
Much of the payment mechanism for Apple’s new iPhone will be powered by a company that most shoppers haven’t even heard of.
First Data Corp., which is owned by private-equity firm KKR& Co., is playing a big role for Apple by providing some of the underlying technology that will allow consumers to pay for purchases with a mobile phone instead of an old-fashioned credit card or debit card.
Atlanta-based First Data is handling part of the all-important security aspect that is aimed at making shoppers confident about using their phone to purchase goods and services.
It is a big catch for First Data, which is unprofitable even though it already handles payment processing and other services for millions of the nation’s merchants and financial institutions.
“Our overriding purpose is to help clients grow their businesses, and a key driver of that is through technology allowing card issuers and merchants, large and small, to bring new payment options to their customers, including revolutionary trends in mobile payments,” said Frank Bisignano, chief executive of First Data, in a press release Tuesday.
In addition to providing security measures on the phone itself, First Data is also working with card issuers so that they can handle a new technology, called tokenization, that replaces cardholder information such as account numbers and expiration dates with a unique series of numbers that validates the customer’s identity.
First Data is also creating software for merchants so that they can accept payments on the new phones.
Since the volume is light the pros are able to do this easily to take out the scared and stops. We will see $125+ by Friday.
Lately the best play has been to buy at $98/$99 area and sell around $108/$110. Shorting at $104 after it's first up day in 4 after an earnings estimate increase is probably not a good idea.
Looks like no one took you up on your offer, $104.85 ask was getting hit right into 8:00pm close. Looks positive for tomorrow but you never know in this wacky market.
"It's an unprecedented deal, Google does not get these kickbacks for providing their services. It's somewhat surprising that Apple was able to negotiate something Google couldn't."
"The list of early Apple Pay partners is impressive, including the 11 biggest US card issuers, representing 83 per cent of the market, and retailers such as McDonald's and Walgreen which together have 220,000 US stores ready to receive iPhone payments."
Furthermore people like myself who have been loyal Samsung/Android users will switch just to have the Apple Watch and Apple Pay functionality. And of course all new Apple Watch customer like myself will have to buy an iPhone as well.
She won't as she received a lot of criticism for making those comments last time. Biotech (or any sector) is not her field so she shouldn't go there.
That's just smart business as they weren't going to make any money if they sold to these poorer countries directly. They created an entirely new revenue stream that requires very little internal resources that they otherwise would of never had. What is the problem with that?
Regarding Solvaldi's price in richer countries - We provide free food to third world countries all the time but you don't hear people from richer countries complain that they have to pay for their groceries. It's the same idea with medicine, poor countries get it free or minimal cost because they don't have the ability to pay, therefore it's the humane thing to do.
Would love to buy more at $95 as I am waiting for next bottom to load up but after Fridays news I doubt it will make it there. If we are lucky we could revisit $98, but if that happens buy quickly as that will be the double bottom it rallies quickly to $115 from.
Since Q1 and Q2 killer earnings we have never had 3 consecutive down days. Too many lined up to buy on any retracements.
GILD's 4th Quarter is going to be off the top of the charts!!!!!
Nobody else has an 8 week program and the lower price will be better suited for providers.
What else would be bringing this down so much despite all the good news lately? When Leon Cooperman said KKR was one of his top picks this was well over $25.
Would of been negative for markets only if ground troops were sent over, which many thought might happen. Basically a non-event as is.
GILD's forward PE is 11 or 12, GSK's is still 12 or 13, which shows you they both have the same forward PE but GILD's growth rate is 7 to 10 times that of GSK.
We already know he added to his stake after CBI tanked as that is documented, we just don't know if he went over the 10% threshold or not.
Do you know why the 10% threshold is important. I remember reading that he may only have to disclose if over 10%, and that it's possible he is buying this month as to not to have to disclose until next month or quarter to give him time to accumulate. I have a feeling he is working on a plan to buy a large stake in CBI as it suits his portfolio and it is the only stock he owns that is discounted 30% this year. He was buying CBI just a few days after that short seller report that tanked CBI (so was David Tepper) so he obviously is a CBI believer despite what the short seller claims.